Recursion Pharmaceuticals Inc. priced its IPO at a level that, with anticipated gross proceeds of $436.4 million, would make it 2021’s second largest biopharma IPO and the eighth largest ever. Salt Lake City-based Recursion’s shares (NASDAQ:RXRX) were priced at $18 each when the market opened and closed April 16’s trading 73.89% higher at $31.30 each. Read More
A collection of CAR T-cell programs originally licensed by Precision Biosciences Inc. to Baxalta Inc. in a $1.6 billion deal are, after handoffs to Shire and Servier SAS, back where they began. Precision said April 15 it would reacquire all development and commercial rights to the programs, including two clinical-stage CD19-targeting allogeneic CAR T candidates, from Servier for $1.25 million in cash, plus the waiver of earned but as-yet unpaid milestones totaling $18.75 million. Read More
DUBLIN – The Biden administration’s proposals on global corporation tax reform have set alarm bells ringing across the Irish government, as officials digest the possible implications of the plan for Ireland's foreign direct investment model of economic development. Read More
With phase III data due from Phathom Pharmaceuticals Inc. in the near term, investor eyes are turning to the ways that lead compound vonoprazan, a potassium-competitive acid blocker, might distinguish itself from proton pump inhibitors (PPIs) in gastroesophageal reflux disease (GERD). Read More
Heidelberg, Germany-based Affimed NV described its progress at the American Association for Cancer Research meeting and discussed the research in a conference call on 2020 financial results, adding fuel to investor enthusiasm for the firm’s natural killer (NK) cell approach, although the update did not come without some confusion. Read More
FDA approvals for biopharma products have reached their highest point in six years for a first quarter, while regulatory data is up a full 45% over last year. A total of 265 regulatory items were tracked by BioWorld in March 2021, representing the highest monthly volume, not only for this year, but for last year as well. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biogen, EMD, Horizon, Implicit, Kintor, Merck KGaA, Quantum Leap, Roche, Takeda, TG. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alexion, Amgen, Astrazeneca, Bold, Brooklyn Immunotherapeutics, Celularity, Factor Biosciences, Five Prime, Gigagen, Immutep, Novellus, Peptron, Portage, Qilu, Relay, ZebiAI, Zogenix. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bausch, Biogen, Chipscreen, Eli Lilly, Oncopeptides. Read More
